EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

Fernando Fernández-García iD, Ana Fernández-Rodríguez iD, Coral Fustero-Torre, Elena Piñeiro-Yáñez iD, Haiyun Wang, Carmen G Lechuga, Sergio Callejas iD, Rebeca Álvarez iD, Alejandra López-García, Laura Esteban-Burgos, Marina Salmón, Marta San Román und 8 weitere

Proceedings of the National Academy of Sciences · 03.09.2024 · 121 (36)

DOI: 10.1073/pnas.2402913121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 26.08.2024. Verfasst von Fernando Fernández-García und 19 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain. Hauptthemen laut MEDLINE: Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Interferon Type I, Signal Transduction. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Spanish Ministry of Science, Innovation and Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident Kras oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically “cold” to immunologically “hot” tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProto-Oncogene Proteins p21(ras)Interferon Type ISignal TransductionImmune Checkpoint InhibitorsMutationAnimalsMiceHumansTumor Suppressor Protein p53Protein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesCell Line, TumorTumor MicroenvironmentAMP-Activated Protein Kinases

Stichwörter der Autor:innen

KRASLKB1interferon signaling pathwaylung cancerp53

Substanzen

Proto-Oncogene Proteins p21(ras)Interferon Type IImmune Checkpoint InhibitorsKRAS protein, humanTumor Suppressor Protein p53Hras protein, mouseProtein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesSTK11 protein, humanStk11 protein, mouse

Autor:innen und Institutionen

  • Experimental Oncology Group, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
  • Bioinformatics Unit, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain.
  • School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
  • Genomic Unit, Centro Nacional de Investigaciones Cardiovasculares, Madrid 28029, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Madrid 28029, Spain.
  • Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy.

ORCID-Profile: Fernando Fernández-García, Ana Fernández-Rodríguez, Elena Piñeiro-Yáñez, Sergio Callejas, Rebeca Álvarez, Carmen Guerra, Chiara Ambrogio, Ana Dopazo, Mariano Barbacid, Monica Musteanu

Förderung

  • Spanish Ministry of Science, Innovation and Universities

Zitieren

APA

Fernández-García, F., Fernández-Rodríguez, A., Fustero-Torre, C., Piñeiro-Yáñez, E., Wang, H., Lechuga, C. G., Callejas, S., Álvarez, R., López-García, A., Esteban-Burgos, L., Salmón, M., San Román, M., Guerra, C., Ambrogio, C., Drosten, M., Santamaría, D., Al-Shahrour, F., Dopazo, A., Barbacid, M., & Musteanu, M. (2024). Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors. Proceedings of the National Academy of Sciences, 121(36). https://doi.org/10.1073/pnas.2402913121

Vancouver

Fernández-García F, Fernández-Rodríguez A, Fustero-Torre C, Piñeiro-Yáñez E, Wang H, Lechuga CG, et al. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors. Proceedings of the National Academy of Sciences. 2024;121(36). doi:10.1073/pnas.2402913121

BibTeX
@article{FernndezGarca2024,
  author = {Fernández-García, Fernando and Fernández-Rodríguez, Ana and Fustero-Torre, Coral and Piñeiro-Yáñez, Elena and Wang, Haiyun and Lechuga, Carmen G and Callejas, Sergio and Álvarez, Rebeca and López-García, Alejandra and Esteban-Burgos, Laura and Salmón, Marina and San Román, Marta and Guerra, Carmen and Ambrogio, Chiara and Drosten, Matthias and Santamaría, David and Al-Shahrour, Fátima and Dopazo, Ana and Barbacid, Mariano and Musteanu, Monica},
  title = {Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {36},
  doi = {10.1073/pnas.2402913121}
}
Kostenlos starten →